Transition of Support for the GORE VIABIL Biliary Endoprosthesis
Olympus Corporation, alongside W. L. Gore & Associates, Inc. and ConMed Corporation, has made a significant announcement regarding the GORE VIABIL Biliary Endoprosthesis in the United States. They collectively revealed the forthcoming transition of commercial support for this important medical device.
Details of the Transition
This transition follows an agreement between Gore and Olympus, granting Olympus exclusive global distribution rights for the GORE VIABIL device. As part of this change, effective January 1, 2026, Olympus will fully take over the distribution of the VIABIL device in the United States. From this date onwards, Olympus representatives will handle all inquiries and orders related to the VIABIL device.
Support Until the Transition
Until December 31, 2025, ConMed will remain actively involved in supporting the GORE VIABIL Biliary Endoprosthesis. This strategy ensures a seamless transition, allowing healthcare providers and patients to experience uninterrupted service. The collaboration prioritizes maintaining the high standards of care associated with the product.
Overview of the GORE VIABIL Device
The GORE VIABIL Biliary Endoprosthesis is a self-expanding metal stent designed to address symptoms linked with biliary strictures effectively. Its innovative design offers a reliable solution for patients suffering from these conditions, ensuring they receive necessary interventions swiftly and efficiently.
Commitment to Patients and Providers
All three companies are dedicated to facilitating a successful transition, focusing on ensuring that both patients and physicians have continual access to this critical medical device. They have pledged to support any queries that may arise during this period.
About Olympus Corporation
Olympus has dedicated itself to enhancing lives by offering innovative medical technology solutions. As a leader in this field, they work closely with healthcare professionals to deliver state-of-the-art solutions for various medical applications, striving to improve patient care standards. With over a century of commitment to innovation and improving health outcomes, Olympus continues to evolve its offerings.
About ConMed Corporation
ConMed Corporation specializes in developing medical devices that cater to various surgical needs. Their products are utilized across multiple surgical specialties, ensuring that surgeons have access to quality equipment necessary for patient care. ConMed's mission aligns with the universal goal of enhancing surgical outcomes through reliable, technological advancements.
About W. L. Gore & Associates
W. L. Gore & Associates has a rich history of focusing on materials science to create solutions that meet industry and consumer needs. Their diverse range of applications extends from critical medical devices to other demanding environments, emphasizing their commitment to innovation and quality. Gore's culture fosters teamwork and creativity, making it a prominent player in the materials science sector.
Frequently Asked Questions
What is the GORE VIABIL Biliary Endoprosthesis?
The GORE VIABIL Biliary Endoprosthesis is a self-expanding metal stent used to relieve symptoms associated with biliary strictures.
Who will manage the distribution after January 1, 2026?
After this date, Olympus will take over the distribution of the GORE VIABIL device in the United States.
What support will ConMed provide until the transition?
ConMed will continue to support the GORE VIABIL device until December 31, 2025, ensuring seamless service for healthcare providers.
Why was the transition announced?
The transition was announced to ensure effective management and distribution of the GORE VIABIL device under Olympus's global distribution rights.
Are there any differences in regional usage of the VIABIL device?
Yes, there may be regional differences in intended use, and it is essential to consult the Instructions for Use for specific details.
